Drugs in Dev. Nephrology
Phase II
Netherlands 
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AM-Pharma Initiates Phase 2 Trial Of Ilofotase Alfa for Kidney Damage
Details : recAP (Ilofotase Alfa), a recombinant alkaline phosphatase, is in Phase 2 trials for cardiac surgery-associated renal damage.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Cowen
Deal Size : $176.0 million
Deal Type : Funding
AM-Pharma Increases Funding To €163m For Phase-Iii Trial Of Recap In Sa-Aki
Details : New capital to be used to support a multi-national pivotal Phase III trial of recAP in 1,400 patients with sepsis-associated-acute kidney injury (SA-AKI).
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Undisclosed
March 31, 2020
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Cowen
Deal Size : $176.0 million
Deal Type : Funding
Reset All
